Orchid Pharma share news, announcements and annual reports
NSE: ORCHPHARMABSE: 524372Pharmaceuticals & BiotechnologySmall Cap
Orchid Pharma Limited · Formerly Orchid Chemicals & Pharmaceuticals · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Dec 1993 on BSE, Jul 2010 on NSE
Last close ₹893.40up ₹28.40 (3.28%)BSE ₹891.95
Share price at the NSE close on 29 Oct 2026. Previous close ₹865.00.
29 Oct: open ₹868.30, high ₹897.40, low ₹860.20
52-week range of traded prices to 29 Oct 2026
₹480.00Low, 30 Mar 2026₹1,143.50High, 22 Sep 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹5,350 Cr919th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Earlier quarters restated in the year
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 0.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.19
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 44,68549.6% delivered
Orchid Pharma share news and announcements
856 announcements, routine notices left out, newest first. Page 18 of 18.
Feb 2007
1 Feb · Business
Orchid has entered into a licensing and distribution agreement with the international generic pharmaceuticals company Actavis, Iceland for marketing 9 of Orchid's cephalosporin generic formulations in Europe. A copy of press release in this regard dated February 01, 2007, titled Orchid in a new licensing and distribution alliance with Actavis to market cephalosporin formulations in Europe" shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jan 2007
24 Jan · Meeting
Notice of the Extraordinary General Meeting to be held on Wednesday, February 14, 2007". A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.22 Jan · Business
Media release dated January 22,2007, titled "Orchid's Betalactam API facility at Aurangabad approved by the UK MHRA". A copy of the media release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.22 Jan · Board meeting
That the following has been considered at a meeting of the Board of Directors of the Company held on Friday, January 19, 2007:- (a) Issue of Warrants - Issue of 5 million Warrants, convertible into Equity Share to the Promoter(s)/Promoter Group(s)/Relatives of Prmoters in accordance with the SEBI Guidelines for Preferential Issue in lieu of 3.56 million unsubscribed warrants as on date. (b) Extraordinary General Meeting - An Extraordinary General Meeting of the Company has been proposed to be held on Wednesday, February 14, 2007 to get the approval of the shareholders in respect of Issue of warrants to Promoter(s)/Promoter Group(s)/Relatives of Promoters.19 Jan · Business
Press release dated January 19,2007, titled "Orchid registers turnover of Rs 239 crore during Q3 FY 2006-07; Net profit stands at Rs 28 crore". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.12 Jan · Board meeting
Meeting of the Board of Directors is proposed to be held on Friday, January 19, 2007, to take on record the un-audited financial results of Orchid for the period from October 01, 2006 to December 31, 2006.